Literature DB >> 19966290

Role of the translocation partner in protection against AID-dependent chromosomal translocations.

Mila Jankovic1, Davide F Robbiani, Yair Dorsett, Thomas Eisenreich, Yang Xu, Alexander Tarakhovsky, Andre Nussenzweig, Michel C Nussenzweig.   

Abstract

Chromosome translocations between Ig (Ig) and non-Ig genes are frequently associated with B-cell lymphomas in humans and mice. The best characterized of these is c-myc/IgH translocation, which is associated with Burkitt's lymphoma. These translocations are caused by activation-induced cytidine deaminase (AID), which produces double-strand DNA breaks in both genes. c-myc/IgH translocations are rare events, in part because ATM, p53, and p19 actively suppress them. To further define the mechanism of protection against the accumulation of cells that bear c-myc/IgH translocation, we assayed B cells from mice that carry mutations in cell-cycle and apoptosis regulator proteins that act downstream of p53. We find that PUMA, Bim, and PKCdelta are required for protection against c-myc/IgH translocation, whereas Bcl-XL and BAFF enhance c-myc/IgH translocation. Whether these effects are general or specific to c-myc/IgH translocation and whether AID produces dsDNA breaks in genes other than c-myc and Ig is not known. To examine these questions, we developed an assay for translocation between IgH and Igbeta, both of which are somatically mutated by AID. Igbeta/IgH, like c-myc/IgH translocations, are AID-dependent, and AID is responsible for lesions on IgH and the non-IgH translocation partners. However, ATM, p53, and p19 do not protect against Igbeta/IgH translocations. Instead, B cells are protected against Igbeta/IgH translocations by a BAFF- and PKCdelta-dependent pathway. We conclude that AID-induced double-strand breaks in non-Ig genes other than c-myc lead to their translocation, and that at least two nonoverlapping pathways protect against translocations in primary B cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19966290      PMCID: PMC2806756          DOI: 10.1073/pnas.0908946107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  79 in total

Review 1.  The mechanism and regulation of chromosomal V(D)J recombination.

Authors:  Craig H Bassing; Wojciech Swat; Frederick W Alt
Journal:  Cell       Date:  2002-04       Impact factor: 41.582

Review 2.  Mechanisms of chromosomal translocations in B cell lymphomas.

Authors:  R Küppers; R Dalla-Favera
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

3.  Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression.

Authors:  Connie Chao; Deron Herr; Jerold Chun; Yang Xu
Journal:  EMBO J       Date:  2006-06-01       Impact factor: 11.598

4.  Mutation of mouse p53 Ser23 and the response to DNA damage.

Authors:  Zhiqun Wu; John Earle; Shin'ichi Saito; Carl W Anderson; Ettore Appella; Yang Xu
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

5.  Exacerbated vein graft arteriosclerosis in protein kinase Cdelta-null mice.

Authors:  M Leitges; M Mayr; U Braun; U Mayr; C Li; G Pfister; N Ghaffari-Tabrizi; G Baier; Y Hu; Q Xu
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

6.  Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL.

Authors:  April Chiu; Weifeng Xu; Bing He; Stacey R Dillon; Jane A Gross; Eric Sievers; Xugang Qiao; Paul Santini; Elizabeth Hyjek; Joong-won Lee; Ethel Cesarman; Amy Chadburn; Daniel M Knowles; Andrea Cerutti
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

7.  AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification.

Authors:  Svend K Petersen-Mahrt; Reuben S Harris; Michael S Neuberger
Journal:  Nature       Date:  2002-07-04       Impact factor: 49.962

Review 8.  Bcl-2-regulated apoptosis: mechanism and therapeutic potential.

Authors:  Jerry M Adams; Suzanne Cory
Journal:  Curr Opin Immunol       Date:  2007-07-12       Impact factor: 7.486

Review 9.  Molecular mechanisms of antibody somatic hypermutation.

Authors:  Javier M Di Noia; Michael S Neuberger
Journal:  Annu Rev Biochem       Date:  2007       Impact factor: 23.643

10.  AID-deficient Bcl-xL transgenic mice develop delayed atypical plasma cell tumors with unusual Ig/Myc chromosomal rearrangements.

Authors:  Alexander L Kovalchuk; Wendy duBois; Elizabeth Mushinski; Nicole E McNeil; Carsten Hirt; Chen-Feng Qi; Zhaoyang Li; Siegfried Janz; Tasuku Honjo; Masamichi Muramatsu; Thomas Ried; Timothy Behrens; Michael Potter
Journal:  J Exp Med       Date:  2007-11-06       Impact factor: 14.307

View more
  8 in total

1.  Translocation-capture sequencing reveals the extent and nature of chromosomal rearrangements in B lymphocytes.

Authors:  Isaac A Klein; Wolfgang Resch; Mila Jankovic; Thiago Oliveira; Arito Yamane; Hirotaka Nakahashi; Michela Di Virgilio; Anne Bothmer; Andre Nussenzweig; Davide F Robbiani; Rafael Casellas; Michel C Nussenzweig
Journal:  Cell       Date:  2011-09-30       Impact factor: 41.582

Review 2.  Origin of chromosomal translocations in lymphoid cancer.

Authors:  André Nussenzweig; Michel C Nussenzweig
Journal:  Cell       Date:  2010-04-02       Impact factor: 41.582

3.  p53 represses class switch recombination to IgG2a through its antioxidant function.

Authors:  Jeroen E J Guikema; Carol E Schrader; Michael H Brodsky; Erin K Linehan; Adam Richards; Nahla El Falaky; Daniel H Li; Hayla K Sluss; Eva Szomolanyi-Tsuda; Janet Stavnezer
Journal:  J Immunol       Date:  2010-05-05       Impact factor: 5.422

4.  Alternative end-joining catalyzes robust IgH locus deletions and translocations in the combined absence of ligase 4 and Ku70.

Authors:  Cristian Boboila; Mila Jankovic; Catherine T Yan; Jing H Wang; Duane R Wesemann; Tingting Zhang; Alex Fazeli; Lauren Feldman; Andre Nussenzweig; Michel Nussenzweig; Frederick W Alt
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-25       Impact factor: 11.205

5.  Checkpoint kinase 2 is required for efficient immunoglobulin diversification.

Authors:  Kathrin Davari; Samantha Frankenberger; Angelika Schmidt; Nils-Sebastian Tomi; Berit Jungnickel
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

6.  ATM increases activation-induced cytidine deaminase activity at downstream S regions during class-switch recombination.

Authors:  Lyne Khair; Jeroen E J Guikema; Erin K Linehan; Anna J Ucher; Niek G J Leus; Colin Ogilvie; Zhenkun Lou; Carol E Schrader; Janet Stavnezer
Journal:  J Immunol       Date:  2014-04-11       Impact factor: 5.422

7.  REG-γ associates with and modulates the abundance of nuclear activation-induced deaminase.

Authors:  Yasuhiro Uchimura; Lance F Barton; Cristina Rada; Michael S Neuberger
Journal:  J Exp Med       Date:  2011-10-31       Impact factor: 14.307

8.  Activation-induced Cytidine Deaminase in B Cell Immunity and Cancers.

Authors:  Seok-Rae Park
Journal:  Immune Netw       Date:  2012-12-31       Impact factor: 6.303

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.